bimekizumab
PS0039
Approved small_molecule active
Quick answer
bimekizumab for Moderate to Severe Plaque Psoriasis, Psoriatic arthritis is a Approved program (small_molecule) at Lacuna Pharma Pty Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Lacuna Pharma Pty Ltd
- Indication
- Moderate to Severe Plaque Psoriasis, Psoriatic arthritis
- Phase
- Approved
- Modality
- small_molecule
- Status
- active